The BAG5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed for loss-of-function studies of the BAG5 gene. This product comprises a heterogeneous pool of cells with targeted BAG5 disruption, suitable for bulk biochemical assays and pooled screening applications where average population effects are desired. The polyclonal format obviates clonal selection bottlenecks and facilitates robust interrogation of BAG5-dependent pathways.
The A-549 host line originates from lung adenocarcinoma tissue of a 58-year-old male and serves as a standard alveolar basal epithelial model. These hypotriploid cells adhere in monolayer cultures and express key signaling molecules relevant to lung cancer biology, providing a disease-appropriate context for investigating BAG5 functions. The cell line is amenable to diverse downstream techniques, including immunodetection, fluorescence microscopy, and metabolic assays.
BAG5 acts as a co-chaperone modulating the Hsp70/Hsc70 chaperone machinery, with roles in apoptosis, autophagy, and proteostasis. Transcriptional induction by HSF1 and ATF4 in response to heat shock or ER stress upregulates BAG5. It directly binds Parkin and Hsp70, forming a complex that inhibits Parkin-mediated mitophagy by preventing Parkin translocation to depolarized mitochondria and reducing mitochondrial substrate ubiquitination. BAG5 also interacts with CHIP and synphilin-1 to influence apoptosis signaling and autophagy flux. Consequently, the BAG5-Hsp70-Parkin axis governs mitochondrial quality control and stress-survival decisions.
In A-549 lung adenocarcinoma cells, BAG5 knockout enables the dissection of co-chaperone contributions to tumor cell proteostasis and oncogenic phenotypes. Lung cancers often exploit altered chaperone activity and defective mitophagy for survival and chemoresistance. Disrupting BAG5 in this model allows assessment of changes in apoptosis susceptibility, autophagy flux, and Parkin-dependent mitophagy, revealing potential cancer vulnerabilities. This model thus connects fundamental chaperone biology with lung adenocarcinoma pathology.
Applications include mitophagy assays using mito-Keima, immunofluorescence for Parkin translocation, and Western blotting for BAG5 and downstream effectors. It is suitable for drug screening targeting the BAG5-Parkin interaction, as well as autophagy and apoptosis modulation assessed by LC3 turnover and flow cytometric viability assays. RT-qPCR enables analysis of compensatory chaperone network changes, and ER stress response studies are supported. For further details, please contact Ascent Research.
